Abstract: Objective To investigate the therapeutic efficacy and adverse reactions of combined Cisplatin and Paclitaxel (TP regimen) or Fluorouracil (PF regimen) with the synchronous radiotherapy to the advanced esophageal carcinoma . MethodsSeventy-two cases with esophageal carcinoma were randomly assigned in TPregimen and PF regimen groups.All the patients received conventional radiotherapy at a total dose of 60～66 Gy (in 30~33 fractions).In TPregimen group,the patients received intravenous infusion of Paclitaxel (135～165 mg/m²) for 3h on day 1 and DDP(20～30 mg/m² daily) on days 1～3,with every 21 days as one cycle.PF regimen consisted of cisplatin (20～30 mg/m2) on days 1～3 and of continuous intravenous infusion of fluorouracil (500 mg/m²) for 5 days,with every 21 days as one cycle. Results No significant differences were found in the survival rates of 1 and 3 years between the TP regimen group (86% and 53%,respectively ) and PF regimen group (83% and 50%,respectively)(χ²=0.148,P=0.701),The same result was also found in the short-term effect.No marked differences of the incidence of all adverse reactions including radiotherapy-induced esophagitis,gastrointestinal reactions and myelosuppression were observed between the two groups(P>0.05). Conclusion Compared with the treatment of esophageal carcinoma using PF regimen,the treatment of esophgeal carcinoma using TP regimen shows the closed therapy efficacy and doesn′t increase the adverse reactions.